Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for booster doses of Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines were presented to the Advisory Committee for Immunization Practices (ACIP) during September–October, 2021. GRADE evidence type indicates the certainty of estimates from the available body of evidence, ranging from type 1 (high certainty) to type 4 (very low certainty).
  
  The policy questions asked whether a booster dose of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine (30 µg, IM), Moderna mRNA-1273 COVID-19 Vaccine (50 µg, IM), or Janssen COVID-19 Ad26.COV2.S Vaccine (5×1010 viral particles, IM) should be recommended for persons aged ≥18 years who completed a COVID-19 vaccine primary series ≥6 months ago (Pfizer-BioNTech, Moderna) or ≥2 months ago (Janssen).
  
  
• Content Notes:
  Overview -- Methods -- Results -- GRADE Summary.
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Evidence-Based Medicine Guidelines As Topic Immunization, Secondary
• Document Type:
  Webpage
• Name as Subject:
  Pfizer-BioNTech COVID-19 vaccine ; COMIRNATY ; Johnson & Johnson’s Janssen COVID-19 vaccine ; Moderna COVID-19 vaccine ; United States. Advisory Committee on Immunization Practices.
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:9f57446304ac35b57f8fef913fda22900ab28cc6537dd11a989d5b4cfc547321
• Download URL:
  https://stacks.cdc.gov/view/cdc/111170/cdc_111170_DS1.pdf
• File Type:
  [PDF - 5.46 MB ]